Biotechnology News and Research

RSS

Hercules Pharma granted rights to license 22nd Century's X-22 smoking cessation aid

22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, announced today that the company licensed Hercules Pharmaceuticals LLC, its wholly-owned pharmaceutical subsidiary, exclusive worldwide rights to X-22.

31 Oct 2011

EBD Group launches partnering360 for life science professionals

EBD Group, the leading partnering firm for the global life science industry, today announced the launch of partnering360, an online network of professionals in the life science industry. partnering360 provides members with a personalized network to the people, the events and the information necessary for partnering success.

31 Oct 2011

New library for development of targeted cancer drugs

In a technical tour de force, scientists at Fox Chase Cancer Center have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 enzymes, including enzymes critical for cancer and other diseases. Additionally, a free library of the results has been made available online to the research community. This unique library represents an important new tool for accelerating the development of an entire class of targeted cancer drugs.

31 Oct 2011

Python heart holds surprises that could be of use in cardiology

The expanding hearts of pythons have intrigued researchers. Leslie Leinwand - a University of Colorado at Boulder molecular biologist who studies heart disease in humans called pythons’ expanding hearts “amazing biology”. “They're not swelling up. They're building (heart) muscle,” he said.

30 Oct 2011

Cranberry juice far better than extracts at fighting urinary tract infections

With scientific evidence now supporting the age-old wisdom that cranberries, whether in sauce or as juice, prevent urinary tract infections, people have wondered if there was an element of the berry that, if extracted and condensed, perhaps in pill form, would be as effective as drinking the juice or eating cranberry sauce. A new study from researchers at Worcester Polytechnic Institute helps to answer that question.

29 Oct 2011

ZIOPHARM reports promising preclinical data with palifosfamide in pediatric sarcoma model

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced the presentation of promising preclinical data with palifosfamide in a pediatric sarcoma model.

29 Oct 2011

Pall, NIBRT co-host master class on single-use systems in manufacturing of biopharmaceuticals

Pall Life Sciences and the National Institute for Bioprocessing Research and Training (NIBRT) in Ireland recently co-hosted a master class on the use of single-use systems in the development and manufacturing of biopharmaceuticals.

From Pall Corporation 29 Oct 2011

BZL and ATLAB Pharma partner to develop 177Lu-J591 for metastatic prostate cancer treatment

ATLAB Pharma SAS and BZL Biologics LLC have entered into a sublicense agreement to develop 177Lu-J591 for cancer treatment. It includes exclusive rights to manufacture, develop and commercialize this radiopharmaceutical product worldwide as well as a joint Phase IIB/III clinical validation program.

29 Oct 2011

Spherix closes private placement transaction

Spherix Incorporated – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today announced the closing of previously announced agreements to sell $1.25 million of shares of its common stock together with warrants to purchase additional shares of its common stock in a private placement transaction.

29 Oct 2011

New drug could combat cardiovascular disease

A new therapy being studied in non-human primates by researchers at Wake Forest Baptist Medical Center and colleagues is demonstrating promise as a potential tool for combating cardiovascular disease by increasing good cholesterol and lowering triglycerides in the blood.

29 Oct 2011

Biogen Idec third quarter revenues increase 11% to $1.3 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its third quarter 2011 results.

28 Oct 2011

DiaGenic reports operating revenue of NOK 276 thousand for third quarter 2011

DiaGenic has successfully finalized the first clinical study in collaboration with Pfizer, the market leader for Alzheimer's therapeutics sales and Pfizer has confirmed DiaGenic's findings resulting in a press release October 14th.

28 Oct 2011

Biogen Idec enters global collaboration for oral Syk inhibitor program with Portola

Biogen Idec and Portola Pharmaceuticals, Inc. today announced that they have entered into an exclusive, worldwide collaboration and license agreement under which both companies will develop and commercialize highly selective, novel oral Syk inhibitors for the treatment of various autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

28 Oct 2011

Intracellular nucleic acid sensors can trigger autoimmune disease

Bruce Beutler, MD, a co-recipient of the 2011 Nobel Prize in Medicine, has coauthored an article describing a novel molecular mechanism that can cause the body to attack itself and trigger an autoimmune disease.

28 Oct 2011

Insight into role of cytokines in autoimmune diseases

Cytokines, a varied group of signaling chemicals in the body, have been described as the software that runs the immune system, but when that software malfunctions, dysregulation of the immune system can result in debilitating autoimmune diseases such as lupus, arthritis, and diabetes. Leading experts in the field of cytokine research present their most up-to-date findings and unique perspectives on the role of cytokines in autoimmune diseases in a special issue of Journal of Interferon & Cytokine Research, a peer-reviewed publication of Mary Ann Liebert, Inc.

28 Oct 2011

Bottom-line boost for Australian Biotechs

Biotechnology companies and international investors are reporting excellent results from this year’s AusBiotech conference, with programs and activities dedicated to helping companies and researchers connect with investors and partners, stirring substantial international interest.

27 Oct 2011

ICON third quarter net revenues increase 7% to $241 million

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the third quarter ended September 30, 2011.

27 Oct 2011

UCB, Emerald BioStructures extend structure-based drug discovery collaboration

Emerald BioStructures today announced a three-year extension of its ongoing collaboration with UCB. The strategic aspects of this renewed relationship will provide Emerald with research funding over the three-year period and the opportunity to receive milestones and royalties on future drug product revenues.

27 Oct 2011

Elan's third quarter total revenue increases 17% to $328.5 million

Elan Corporation, plc today reported its third quarter and first nine months 2011 financial results.

27 Oct 2011

BGI, UC Davis partner to create new sequencing facility in Sacramento

The University of California, Davis, and BGI, the world's largest genomic institute, based in China, have signed a historic agreement that will change the landscape of genomic sciences in California and the Western states, and foster critical breakthroughs in the areas of food security and human, animal and environmental health.

27 Oct 2011